Key summary: In our national cohort of Veterans with initial mild Clostridium difficile infection (CDI) and treated with metronidazole, age < 65 years was the only predictor of success 30-days post treatment (absence of 2 mortality or recurrence). Among these younger patients with mild CDI, success rates were similar with metronidazole and vancomycin. 
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Clostridium difficile has become the most common cause of healthcare associated infections in the United States. [1] For over three decades metronidazole has been the mainstay of treatment for initial cases of mild to moderate Clostridium difficile infection (CDI). [2] Until recently, metronidazole was recommended as the first-line treatment option over vancomycin for initial cases of mild-moderate CDI. [2, 3] In early 2018, updated clinical practice guidelines from the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) were released, which no longer recommend metronidazole for initial nonsevere CDI as per previous guidelines from 2010. [2, 3] Updated guidelines only distinguish severe disease from non-severe disease (previously defined as mild-moderate disease), and 2010 guidelines do not distinguish between mild and moderate disease. [2, 3] This substantial change in non-severe CDI treatment recommendations is largely based off evidence demonstrating better outcomes associated with vancomycin as compared to metronidazole in patients with severe CDI. [4, 5] Among patients with mild CDI, several studies have demonstrated no difference between vancomycin and metronidazole for mortality, CDI recurrence or clinical cure. [4] [5] [6] When metronidazole is used per 2010 CDI guidelines in certain patients with mild-moderate disease it may still have similar effectiveness to vancomycin. Metronidazole is less expensive and may be associated with lower colonization and/ or development of drug-resistant organisms compared with vancomycin. [7, 8] Since publication of the updated guidelines, expert correspondence has recommended continued consideration of metronidazole as a first-line option for patients with mild CDI and a low risk for disease complications. [8] Limited data exists to guide clinicians in identifying in which patients metronidazole may still be used. As such, first we sought to identify independent predictors of success (defined as absence of mortality or recurrence) among a national cohort of Veterans with mild CDI treated with metronidazole per 2010 CDI guideline recommendations. Then, we sought to compare the effectiveness of metronidazole with vancomycin in patients with mild CDI. Characteristics associated with success were used to identify the subgroup for our comparative effectiveness analysis.
METHODS

Study Population
A cohort of Veterans with a first CDI episode (defined as a stool sample positive for C. difficile toxin(s) and > 2 days of CDI treatment) from May 1, 2010 to December 30, 2014 was used. [9] CDI episodes from inpatient and outpatient settings from 125 VA centers nationally were included. Only patients with mild disease (defined as a white blood cell count (WBC) <15 x 10 3 /μL and a serum creatinine (SCr) was <1.5 mg/dL within 7 days of CDI treatment) and those treated per guidelines (10-14 days of monotherapy with oral metronidazole or oral vancomycin) were included. [2] Patients with missing WBC or SCr were excluded.
Study Design
We conducted a two-stage analysis among our large national cohort of Veterans with mild CDI, first conducting a predictive analysis and second a comparative effectiveness analysis.
Predictive Analysis.
We compared patients with and without successful outcomes with a mild first CDI episode treated with metronidazole monotherapy. Patients with success were those who did not die or have a CDI recurrence at day 30, and patients without success were those who died or had a CDI recurrence within 30 days post-treatment (failures). CDI recurrence was defined as another CDI positive stool sample or CDI diagnosis code (008.45) and at least two days of subsequent CDI treatment at least 14 days after the initial positive stool sample and within 30 days post-treatment of the initial episode. Our a priori definition of recurrence was a subsequent episode within 30 days post-treatment, as recurrence risk is greatest within 10 days post-treatment and in clinical trials recurrence is commonly defined within 28-30 days post-treatment. [10, 11] Predictors assessed are presented in Table 1 . Treatment setting (acute, long-term care, or outpatient) was defined based on patient location at the time of positive stool sample. Comorbidities were identified using International Classification of Diseases, 9
th Revision (ICD-9) diagnosis and procedure codes within the one year prior to the first CDI episode or during treatment. The Clinical Classifications Software of the Agency for Healthcare Research and Quality and previously described disease categorizations were used to group specific diagnoses and procedures into broader disease state groups.[12, 13] ICD-9 codes were also used to identify previous and current infections and other acute events. Comorbidity burden was assessed using Charlson comorbidity index and Elixhauser score. All medication exposures were defined as binary variables and windows of exposure were selected based on clinical relevance or previous work.[ [14] [15] [16] Inpatient and outpatient pharmacy data were utilized to determine all medication exposures and CDI treatment duration. Hypervirulent strain was defined as presence of NAP1/027 where strain type data was available and not hypervirulent/unknown strain in the absence hypervirulent strain type or where strain type was missing. Overall, 45 potential predictors were selected a priori and assessed. [2, 14, [17] [18] [19] Comparative Effectiveness Analysis.
In the second phase of our study, we conducted a comparative effectiveness analysis of metronidazole versus vancomycin on outcomes among Veterans in a select subgroup of our mild CDI cohort. We used characteristic/s predictive of success with metronidazole identified in the first stage of our study, to select the subgroup to compare clinical outcomes with metronidazole and vancomycin. The primary exposure of interest was CDI treatment (metronidazole or vancomycin). The outcomes of interest were 30-day all-cause mortality, 30-day CDI recurrence, and a composite failure outcome (lack of success as defined above). Numerous covariates, which may confound the association between CDI treatment and poor clinical outcomes in patients with CDI, were identified and measured a priori based on underlying causal beliefs. [2, 14, [17] [18] [19] 
Statistical Analysis
Predictive Analysis.
We used backwards, manual, stepwise unconditional logistic regression to identify independent predictors of success among patients with a mild first CDI episode treated with metronidazole. [20] Variables from univariate analysis with a p-value of <0.10 were included in subsequent multivariable analysis and removed one-by-one from the multivariable model until all remaining variables had a p-value <0.05. [20] Tolerance and variance inflation were used to confirm the absence of collinearity between potential predictors. [20] Comparative Effectiveness Analysis.
Propensity-score matched Cox proportional hazards models were used to quantify the effect of vancomycin versus metronidazole on time to 30-day all-cause mortality, CDI recurrence, and failure among a subgroup of patients with characteristic/s associated with metronidazole success. [21] Propensity scores were developed for exposure to metronidazole compared with vancomycin as function of all potential confounders which was modeled using logistic regression. [21] The predicted probability of exposure for each patient (propensity score)
was estimated using this model. We assessed common support (overlapping distributions of the propensity score between exposure groups) using visual comparison. [21, 22] We performed nearest-neighbor 1:1 propensity score matching within 0.01 caliper. To assess balance of potential confounders, standardized biases (absolute standardized difference in means) were examined for the original and matched samples. [22] Crude and matched hazard ratios were calculated using Cox proportional hazard regression models. Cox proportional hazard regression proportionality assumptions were assessed.
RESULTS
Predictive Analysis.
Among 3,656 patients with mild CDI and treated with metronidazole, we identified 3,282 patients with success at day 30 post-treatment and 374 patients without success (failure). Several significant differences between patients with and without success were observed (Table 1) . In multivariable analysis, younger age was the only independent predictor of success identified ( Table 2 ). The odds of success was 1.63 times (95% confidence interval [CI] 1.29 -2.06) higher among patients 65 years of age or younger as compared to those over 65 years of age. There were several predictors of failure identified (odds ratios <1, Table 2 ) including: a principle diagnosis of CDI, current intestinal infection, current respiratory failure, malignancy, previous hospital or long-term care exposure, hypoalbuminemia, body mass index (BMI) > 30 kg/m 2 , and previous probiotic exposure.
Comparative Effectiveness Analysis.
For the comparative effectiveness analysis, a mild CDI cohort of younger patients 65 years of age or younger was selected. Predictors of treatment and of failure were included in the propensity score model. Baseline characteristics were well balanced in the propensity score matched cohort (115 matched pairs, Table 3 ). Among the propensity-score matched cohort, no significant differences were observed between metronidazole and vancomycin (reference) for the outcomes assessed (Table 4) .
DISCUSSION
To our knowledge this study is the first to focus specifically on identifying predictors of success and comparing treatment options in patients with an initial episode of mild CDI. This work suggests that metronidazole may still be an appropriate treatment option for younger patients with initial mild CDI.
Age was the only predictor of success identified and may be one of the most important factors when considering which patients with initial mild disease may still be candidates for metronidazole therapy. Within hospital and long-term care settings, the patients are typically older, have an increased exposure to antibiotics and gastric acid suppressants, and environmental exposure to C. difficile spores, thus are at an increased risk for the development of initial and recurrent CDI. [10] These factors may also contribute to an increased risk for severe disease and mortality.
Factors, such as hypoalbuminemia, respiratory failure and intestinal infection, which may be markers of severe or complicated disease, were also predictive of failure. Underlying comorbidities and hypoalbuminemia are among the most commonly reported risk factors for poor outcomes. [15] While not included in the IDSA/SHEA definitions for severity, hypoalbuminemia is included in other criteria to define severe disease. [5, 31] While antibiotic use was not identified as an independent predictor in our study, antibiotic use is another frequently reported risk factor for poor outcomes in patients with CDI. [15] Patients with comorbid respiratory failure or intestinal infections during a CDI episode may be exposed to non-CDI active antibiotics for these conditions during their CDI treatment. It is also possible an intestinal infection diagnosis may not be due to another infection but may be due to CDI symptoms themselves. Our findings suggest that severe underlying comorbidities and other markers of severity in addition to those of the IDSA/SHEA, particularly albumin level, should be considered when determining which patients have mild disease that can be treated with metronidazole. [31] Continued work is needed to investigate which severity criteria are most useful in defining mild disease that can be successfully treated with metronidazole.
Obesity (BMI > 30 kg/m 2 ) was also identified as a predictor of failure. Previous work has identified obesity as a risk factor for the development of CDI. [30] There is also evidence that obesity is associated with more severe There are limitations to our retrospective study. We were interested in assessing guideline concordant treatment thus required a CDI treatment duration of 10 to 14 days per guideline recommendations and that laboratory values be measured to assess disease severity. Our results may not be generalizable to more mild cases that resolve sooner than 10 days or more severe or complicated cases that require treatment longer than 14 days or those in which SCr and WBC were not collected. The VA population consists primarily of older White males and as such generalizability of this study to the general population may be limited.
Misclassification of outcomes and covariates may impact our results. A priori, we chose to study 30-day CDI recurrence from the end of therapy, because most cases of CDI recur within 1-3 weeks after treatment. [10, However, the previous national VA study that compared vancomycin and metronidazole assessed for recurrence up to 56 days after the initial CDI diagnosis and similar to our findings found no difference between therapies on risk of recurrence. [6] We only accounted for treatment and care in the VA system, therefore there is the potential that we may of misclassified recurrence in patients who received care for their recurrent episode outside the VA system. Our success and failure outcomes are composite outcomes that include mortality and recurrence and they have not been used previously. We were not able to assess the resolution in CDI symptoms, so composite endpoints did not include treatment failure (continued diarrhea) which is another common poor outcome of CDI. [40] As a consensus definition for CDI-attributable mortality is not established, we measured all-cause mortality. It is possible that some of the deaths we observed were attributable, at least in part, to diseases other than CDI.
In our observational comparative effectiveness analysis, since there was no randomization of patients to either metronidazole or vancomycin, confounding by indication is a chief concern. During the study time period metronidazole was recommended first-line for mild-moderate disease and vancomycin was recommended for severe disease. [2] Due to the differences in treatment recommendations, patients treated with vancomycin at baseline were inherently different than those treated with metronidazole, and at a higher baseline risk of poor outcomes. We used restriction and propensity score matching in an attempt to reduce this confounding bias.
Facility was included in the propensity score as there is no national VA policy for the treatment of CDI, and CDI treatment decisions could vary by facility. While our propensity score included all observed confounders related to the use of metronidazole and vancomycin in our study population, there is the potential for residual confounding due to unknown factors and known but unmeasurable factors, such as cytokine responses to CDI.
Due to the small sample size in the propensity score matched analysis, random error may have impacted the observed results.
Our findings among a national cohort of Veterans with an initial episode of mild CDI provide clinicians guidance on patients in whom metronidazole therapy may still be considered. Age was the only predictor of success identified and among patients aged <65 years we found no difference between metronidazole compared with vancomycin on risk of 30-day all-cause mortality, CDI recurrence, or a composite of the two outcomes. Other factors, such as a primary diagnosis of CDI on hospital admission, severe underlying comorbidities, and hypoalbuminemia were associated with failure and in patients with these conditions, alternative therapy with vancomycin or fidaxomicin should be considered. The adjusted odds ratios are estimated from multivariable analysis of the data. The final multivariable unconditional logistic regression model included all variables in Table 2 . Success was defined as absence of death from any cause or CDI recurrence within 30 days from the end of treatment of the initial episode. Those with success were those who experienced success at day 30, and those without success (failures) were those who died or recurred within 30 days from end of treatment. Thus, variables with an odds ratio greater than one were independent predictors of success, and those with an odds ratio less than one were predictors of failure. 
